1000/1000
Hot
Most Recent
The syndromes of neurodegeneration with brain iron accumulation (NBIA) encompass a group of invalidating and progressive rare diseases that share the abnormal accumulation of iron in the basal ganglia. The onset of NBIA disorders ranges from infancy to adulthood. Main clinical signs are related to extrapyramidal features (dystonia, parkinsonism and choreoathetosis), and neuropsychiatric abnormalities. Ten NBIA forms are widely accepted to be caused by mutations in the genes PANK2, PLA2G6, WDR45, C19ORF12, FA2H, ATP13A2, COASY, FTL1, CP, and DCAF17. However, many patients remain without a genetic diagnosis, and therefore, there must be additional yet undiscovered NBIA genes. The genetic heterogeneity and the corresponding encoded proteins emphasize that several pathways are involved in NBIA syndromes: iron and lipid metabolism, mitochondrial dynamics, and autophagy. Moreover, for these forms as well as for many neurodegenerative conditions, mitochondrial dysfunction and oxidative stress are common mechanisms of disease.
Ten genes are classically accepted as NBIA genes[1].The two major forms are PKAN (pantothenate kinase-associated neurodegeneration; 35–50%; PANK2 gene) and PLAN (PLA2G6-associated neurodegeneration; ~20%; PLA2G6 gene), followed by MPAN (mitochondrial membrane protein-associated neurodegeneration; 6–10%; C19ORF12 gene) and BPAN (β-propeller-associated neurodegeneration; 1–2%; WDR45 gene). FAHN (fatty acid hydroxylase-associated neurodegeneration; FA2H gene), NF (neuroferrinopathy; FTL gene), aceruloplasminemia (CP gene) and Woodhouse–Sakati syndrome (DCAF17 gene) are rare types. Finally, two probands and five probands, respectively, are described for Kufor–Rakeb syndrome (ATP13A2 gene) and CoPAN (COASY protein-associated neurodegeneration; COASY gene). Importantly, a relevant number of patients with NBIA have no genetic diagnosis, suggesting that other implicated genes remain to be discovered.
PANK2 encodes for the mitochondrial isoform of pantothenate kinase that catalyzes the ATP-dependent phosphorylation of pantothenate, an essential regulatory step in CoA biosynthesis (Figure 1). The PANK2 protein, located in mitochondria, has two domains: one that includes two MLS (mitochondrial localization signals) in the NH2-terminal and the other large one that encodes for the catalytic core of the enzyme[2][3]. To date, more than 120 disease-causing mutations are known in PANK2 (HGMD® Professional 2020.1; accessed 8 October 2020).
Two main subtypes are associated with the autosomal recessive (AR) disorder PKAN: classical (early onset, usually before 6 years of age) or atypical (first symptoms in early adulthood). The classical presentation is characterized by dystonic tremor with predominant oromandibular involvement, optic atrophy, pigmentary retinopathy, acanthocytosis, and spasticity. In the late-onset PKAN form, motor involvement tends to be less severe but cognitive decline and psychiatric alterations are predominant traits[4][5]. In PKAN patients, the characteristic “eye of tiger sign” is detected by T2-weighted magnetic resonance, which reflects the focal accumulation of iron in the globus pallidus (GP)[6][7]. The iron accumulation correlates with neural damage, often associated with neuroaxonal spheroids that represent degenerating neurons in GP[8][2].
In addition to this, neuronal degeneration promotes a mild inflammatory response due to infiltrations of iron-containing macrophages, astrogliosis and microglial activation[9]. These findings suggest that chronic neuronal hypoxia and/or ischemia in the GP may play an important role in the pathomechanism of PKAN.
CoA synthase, a bifunctional enzyme that catalyzes the last two steps in CoA biosynthesis, is encoded by the COASY gene (Figure 1). The protein contains a mitochondrial localization signal, a regulatory region and two domains for its catalytic kinase activities, 40PP adenyltransferase (PPAT) and dephospho-CoA kinase (DPCK), and it is predominantly located at the mitochondrial matrix. Mutations in this gene lead to CoPAN, an ultra-rare NBIA form inherited in an AR manner. Hitherto, four CoPAN families are known[10][11] and three missense variants have been described (HGMD® Professional 2020.1; accessed 10 September 2020). All these patients show typical NBIA features: onset in the first decade of life with mild cognitive impairment and gait difficulties, progressing to a more severe phenotype including dystonia, parkinsonism, dysarthria, spasticity and axonal neuropathy. Obsessive-compulsive disorder is also a common featurein CoPAN patients.
AR mutations in the phospholipase A2 group (PLA2G6) are causative of the PLAN phenotypic spectrum, including classic infantile neuronal dystrophy (INAD), atypical neuronal dystrophy (NAD) with childhood-onset, and an adult onset dystonia-parkinsonism form named PARK14[12]. This NBIA type is characterized by progressive motor deterioration and may lead to spastic or hypotonic tetraparesis with truncal hypotonia, cerebellar ataxia, early optic atrophy, seizures in later stages of the disease, dystonia, and cognitive impairment[13]. The most typical sign of INAD is a fast progression of cerebellar atrophy in early stages. At later stages of the disease progression, most INAD patients usually show brain iron accumulation in the GP and the substantia nigra[14][15]. About 200 distinct mutations in PLA2G6 of all types (missense, deletions, frameshift, nonsense, splice site), including multiexon deletion and duplication[16][17] have been published (HGMD® Professional 2020.1; accessed 15 September 2020).
Because PLAN is caused by biallelic mutations, the disease mechanism is expected to be caused by loss of function. PLA2G6 encodes several isoforms of VIA calcium-independent phospholipase A2, which hydrolyzes the sn-2 ester bond in membrane phospholipids, releasing free fatty acids and 2-lysophospholipids[18] (Figure 1). It is involved in transduction and maintenance of phospholipid homeostasis, releasing docohexaenoic acid (DHA) and arachidonic acid[19]. In addition, roles related to inflammation and immune responses, chemotaxis, vascular relaxation, secretion and apoptosis have been described for this phospholipase[20][21].
Mutations in the C19ORF12 (chromosome 19 open reading frame 12) gene cause MPAN, which is characterized by cognitive decline progressing to dementia, speech and gait disturbances, parkinsonism, optic atrophy and motor axonal neuropathy[22]. The first C19ORF12 mutation discovered was a homozygous 11 bp deletion leading to a truncated protein (c.204_214del11, p.Gly69Argfs*10)) in 13 families from Eastern Europe[23]. Nowadays, about 50 C19ORF12 variants have been found to relate to the MPAN phenotype, including missense/nonsense, indels and splicing mutations (HGMD® Professional 2020.1; accessed 7 October 2020). Although MPAN is considered an AR condition, a single C19ORF12 mutation can lead to the same clinical phenotype as biallelic variants[24]. C19ORF12 synthesizes a small transmembrane protein (17 kDa), whose function remains unclear (Figure 1). It is widely expressed in the brain and adipocytes and localized in the lumen and MAMs (mitochondria associated membranes) of mitochondria, and in the ER.
Mutations in FA2H (fatty acid 2-hydroxylase) cause AR FAHN. Clinically, FAHN is characterized by ataxia, dystonia, spasticity, ocular abnormalities, cerebellar atrophy, and iron deposition, predominantly in the GP. Cognitive impairment and seizures may be features of the disease[25]. White matter abnormalities, a thinner corpus callosum and supratentorial atrophy seem to be hallmarks shared by the vast majority of the patients[26]. Up to 65 mutations (missense/nonsense, frameshift, splicing and indels) in FA2H have been described (HGMD® Professional 2020.1; accessed 7 October 2020). FA2H encodes a NADPH-dependent mono-oxygenase that colocalizes with the ER membrane. FA2H is crucial during the early stages of brain development. Due to its 2-hydroxylase activity, FA2H produces 2-hydroxylated ceramides and therefore, participates in myelin formation[27] (Figure 1).
BPAN disorder is caused by mutations in the X chromosome gene WDR45, which is transmitted in an AD manner. To date, all affected individuals are sporadic cases with no family history (de novo mutations). Clinical features do not always follow the typical pattern for an X-linked disorder. Apparently, affected men, who are carriers of hemizygous WDR45 mutations, are predicted to harbor post-zygotic mutations, suggesting that male patients could be somatic mosaicisms[28]. Affected women may carry either germline or somatic mutations, showing different phenotypic manifestations, probably associated with skewing of X chromosome inactivation[29]. So far, about 112 disease-causing mutations are known in WDR45 (HGMD® Professional 2020.1; accessed 13 October 2020).
Clinically, BPAN is well characterized as a two-stage disease progression. The first stage comprises a global developmental delay in childhood with intellectual disability. Common early comorbidities comprise seizures, spasticity, and epilepsy. The second stage affects all patients in early adulthood, and manifests with progressive dystonia, dementia and parkinsonism characterized by bradykinesia and rigidity without tremor. Brain magnetic resonance imaging (MRI) shows iron accumulation in the substantia nigra and globus pallidus in the early phase. A T1-weighted hyperintense “halo” signal with a central band of hypointensity in the substantia nigra seems to be a specific finding in BPAN. Cerebral atrophy is also reported in most patients. Additional symptoms are sleep disturbance, ocular features and Rett-like hand stereotypies[29].
The WDR45 protein is a member of the WD40 repeat protein family with a β-propeller platform structure. WD40 proteins play a role in coordinating protein–protein interactions in order to perform a variety of functions, such as signal transduction, autophagy or transcriptional regulation. In particular, the WDR45 protein, by binding to phosphatidylinositol-3-phosphate (PtdIns3P), regulates autophagosome formation[30].
Kufor–Rakeb disease (KRD) is a very rare early-onset atypical parkinsonism caused by mutations in the ATP13A2 gene with AR inheritance. Symptoms appear before 20 years of age and are characterized by motor symptoms (pyramidal degeneration) and non-motor symptoms (dementia, learning difficulties and hallucinations)[31][32]. About 50 mutations associated with KRD, including additional phenotypes such as neuronal ceroid-lipofuscinosis and hereditary mutations, have been reported in ATP13A2 (HGMD® Professional 2020.1; accessed 16 September 2020)[33]. Most patients with AR parkinsonism do not accumulate iron in the brain despite being clinically symptomatic. Nevertheless, some cases with homozygous mutations in ATP13A2 and evidence of iron deposition in the basal ganglia have been reported, which makes it possible to include KRD in the NBIA group of disorders[34][35]. ATP13A2 encodes for a lysosomal 5P-type ATPase, and is mostly localized in endosomes, lysosomes, and partially, in autophagosomes (Figure 1). Several functions have been attributed to ATP13A2 including homeostasis of manganese, zinc and iron, allowing active transportation across endosomal and lysosomal membranes, mitochondrial bioenergetics and the autophagy-lysosomal pathway. Defects in ATP13A2 may impair the endo-lysosomal and autophagy flux, resulting in the accumulation of insoluble proteins and damaged mitochondria, leading to apoptosis and neuroinflammation.
Aceruloplasminemia is a rare AR disorder caused by mutations in the CP gene, which encodes for ceruloplasmin (Cp), a multicopper ferroxidase functioning as an iron exporter from cells[36]. Intracellular Fe2+ is transported by ferroportin to transferrin via the ferroxidase activity of ceruloplasmin (Fe2+ -> Fe3+) (Figure 1). Close to 70 mutations (missense, frameshift, splicing, nonsense) have been described in CP (HGMD® Professional 2020.1; accessed 16 September 2020). Homozygous mutations are identified in the vast majority of patients, although compound heterozygosity may be also detected. Even though inheritance is AR, heterozygous carriers may present with a milder clinical picture[37]. Cp function is essential in astrocytes as it is the only ferroxidase in this cell type. Its absence causes remarkable morphological abnormalities, oxidative stress due to iron accumulation, and lipid peroxidation. These features are also present in other brain tissues, being severe in the basal ganglia, thalamus and cerebellum of the patients, which supports toxicity of iron excess[38]. The CP-associated phenotype is characterized by dementia, ataxia, chorea and parkinsonism in adulthood[39]. Microcytic anemia, liver disease and retinopathy are also common clinical features.
Mutations in the ferritin light chain (FTL) gene cause neuroferritinopathy, an AD inherited disease with adulthood onset. So far, ten nucleotide duplications in exon 4 (HGMD® Professional 2020.1; accessed 10 September 2020), involving COOH-terminal residues of the protein, are associated with NF, and they may account for dystonia, dysarthria, cerebellar signs, parkinsonism, chorea and psychiatric features[40]. Ferritin removes ferrous iron from labile iron pools in cells in order to prevent cellular damage, oxygen reactive species formation, lipid peroxidation, protein aggregation and iron overload, common features of NF (Figure 1). Iron is stored in the form of ferric iron oxide inside ferritin, which is responsible for its release when it is required by cellular pathways. Native human ferritin is a heteropolymer composed of two subunits: FTH1 and FTL. Each cell/organ presents different ratios of these subunits depending on their storage rate and optimization. COOH-terminus modifications seem to result in an alteration of the heteropolymeric structure that prevents iron from binding, and promotes the generation of ferritin aggregates and the formation of inclusion bodies[41]. As this is a consequence of long-term stress conditions, development of the disease is gradual in the patients.
Woodhouse-Sakati syndrome is a rare AR disorder caused by mutations in the DCAF17 gene. To date, a total of 17 variants related to this syndrome have been described, including five missense mutations, six splicing mutations, and 12 small insertions or deletions (HGMD® Professional 2020.1; accessed 8 October 2020). The complex clinical picture is characterized by the effects on SNC, but also on the SNP and the neuroendocrine system. Some of the Woodhouse-Sakati traits are hypogonadism, diabetes mellitus, mental retardation, deafness, alopecia, polyneuropathy and extrapyramidal impairment[42][43]. This gene encodes a nucleolar protein (Figure 1) expressed in many tissues, including the brain, liver, skin and gonads. The function of Dcaf17 is still unknown, but it is related to the Dcaf gene family and is involved in apoptosis, DNA methylation and cell cycle regulation[44].
NBIA syndromes share the distinctive feature of iron overload in the brain and present a wide genetic heterogeneity with genes related to disparate pathways. How these different genes can cause the abnormal deposits of iron in the brain is a matter of investigation. However, as usually occurs in many other neurodegenerative disorders, mitochondrial dysfunction may play a vital role in the underlying pathomechanism because of the high energy demand within the brain. NBIA genes directly related to mitochondrial functions are PANK2, COASY and probably, C19ORF12, which ultimately together with PLA2G6 and FA2H are involved in phospholipid membrane synthesis (Figure 1). WDR45 is crucial in the formation/degradation of autophagosomes as well as ATP13A2, a lysosomal protein. Lysosomal activity is essential for iron homeostasis in which FTL and CP take part. As a whole, the disease process in at least seven NBIA forms involves mitochondrial dysfunction, which produces oxidative stress and leads to neuroinflammation. Nonetheless, the list of NBIA genes is growing and the connection between all the players involved in NBIA disorders is unclear. Further studies are necessary with the aim of characterizing targets for therapeutic interventions.